In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • A Retrospective Study on Gadolinium-Based Contrast Agents and Their Role in the Management of Asymptomatic Meningiomas

    Final Number:
    1323

    Authors:
    Joy He BA; Michael Zhang MD; Michael Iv; Gordon Li MD; Melanie Hayden Gephart MD, MAS

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: Gadolinium-based contrast agents (GBCA) are necessary to enhance MRI studies. However, patients can have adverse allergic reactions. GBCA deposits in the brain[5-8] and dechelated gadolinium is toxic[1,2]. In 2006, the FDA issued a black box warning given the dose-dependent relationship between MRI contrast and the rare but serious adverse event of nephrogenic systemic fibrosis[3,4]. Patients with meningiomas require regular MRIs over decades, and the risk of contrast administration must be balanced with the need to monitor for interval tumor growth[9]. We hypothesized that non-contrast MRI sequences such as T2/FLAIR could determine growth in convexity meningiomas. Our study aims would allow us to reduce unnecessary contrast administration by demonstrating that non-contrast MRIs accurately monitor convexity meningioma growth.

    Methods: This Institutional Review Board (IRB)-approved retrospective chart review included 106 MR sequences from 18 patients. Inclusion criteria were adult patients with asymptomatic convexity meningiomas who received baseline contrast-enhanced and non-contrast axial MRI imaging of the brain. Exclusion criteria included the following: 1) baseline or follow-up axial images were not available 2) baseline scan was obtained without contrast 3) the diagnosis of meningioma was later disputed. Percent tumor growth was measured by comparing cross-sectional area measured at maximum tumor diameter from the earliest and most recent scan. For each patient, change in tumor size over time was compared using T1+ contrast, T2, and T2 FLAIR sequences. These were compared to a qualitative consensus reading by a neurosurgeon and a neuroradiologist.

    Results: Tumor growth of less than 10% was taken to represent stability. In 17/18 patients, noncontrast studies (T2, T2 FLAIR) accurately assessed tumor growth compared to consensus. For one patient, noncontrast studies indicated 12% growth while consensus was stability.

    Conclusions: Our results suggest non-contrast MRI images may be equivalent to contrast weighted MRI images to follow change in tumor size over time in asymptomatic convexity meningiomas.

    Patient Care: This research directly impacts patient care by providing an alternative to contrast-based MR studies for the long term monitoring of convexity meningiomas. This reduces patient time in the hospital, reduces the cost of management, minimizes needle sticks, and decreases the potential for allergic reactions and adverse effects of contrast such as NSF.

    Learning Objectives: By the conclusion of this session, participants should be able to 1) describe the risks of long term gadolinium exposure and 2) identify alternative MR sequences for monitoring tumor growth in meningioma patients over time

    References: 1. Sherry, A.D., P. Caravan, and R.E. Lenkinski, Primer on gadolinium chemistry. J Magn Reson Imaging, 2009. 30(6): p. 1240-8. 2. Sanyal, S., et al., Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review. Nephrol Dial Transplant, 2011. 26(11): p. 3616-26. 3. Errante, Y., et al., Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol, 2014. 49(10): p. 685-90. 4. Collidge, T.A., et al., Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology, 2007. 245(1): p. 168-75. 5. McDonald, R.J., et al., Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology, 2015. 275(3): p. 772-82. 6. Kanda, T., et al., Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. Radiology, 2015. 276(1): p. 228-32. 7. Kanda, T., et al., High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology, 2014. 270(3): p. 834-41. 8. McDonald, R.J., et al., Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities. Radiology, 2017: p. 161595. 9. Oya, S., et al., The natural history of intracranial meningiomas. J Neurosurg, 2011. 114(5): p. 1250-6.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy